Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Antex Biologics (ANTX) -- Ignore unavailable to you. Want to Upgrade?

To: Amigo Mike who wrote (1467)	6/6/2000 11:43:00 AM
From: R Hamilton	Read Replies (1) \| Respond to of 1476

sounds good to me, but what do i know........let me see a big pharma show some interest and the $$ and i will get excited. Antex Develops New Technology to 'Blueprint' Infectious Disease PR Newswire, Tuesday, June 06, 2000 at 10:58 VEP(TM) Will Accelerate Novel Antibiotic and Vaccine Discoveries GAITHERSBURG, Md., June 6 /PRNewswire/ -- Antex Biologics (BB:ANTX) today announced the development of its new genomics-based platform technology that reveals the "blueprint" of infectious bacteria in their host environment. Using the new VEP(TM) (Virulence Expression Profiling) platform, Antex can duplicate in the laboratory the way bacteria grows in the human body and identify the disease-causing ("virulence") proteins of a bacteria at the genomic level. Believed to be the only such bacterial virulence protein-identification technology in the world, Antex scientists will use VEP to accelerate the development of new vaccines and antibiotics that will prevent infectious diseases and kill bacteria. Efficient disease related protein identification offers considerable competitive advantage by speeding up drug and vaccine discovery. "There is a great deal of excitement about this innovative technology. We believe VEP will significantly streamline Antex's drug discovery and vaccine development programs," said Dr. Larry Ellingsworth, Vice President Research and Development at Antex. "Ultimately, VEP will lead Antex to new antibiotic and vaccine discoveries that will fight infectious diseases, such as Strep and Staph infections that are becoming increasingly resistant to antibiotics now available." VEP combines Antex's patented NST(TM) (Nutriment Signal Transduction) technology, which duplicates in the laboratory certain important environmental conditions microbes encounter in the human body, with the latest ways to identify genes using genomic microarray expression profiling tools. These genomic tools provide a rapid and systematic method for the high-throughput analysis of genome-wide gene expression from complex biological samples. The net result is an extremely high identification rate of proteins that cause disease. Current antibiotics work against just a few disease-related proteins in the body, or "targets," as the industry calls them. VEP, Antex's new genomics-based technology, should yield a quantum leap revealing many new targets as well as antigens for use as vaccines. NST technology works by identifying the particular signals, natural chemicals and other in vivo conditions ("nutriments") that transduce bacteria and enhance the expression of specific virulence properties. NST-grown microbes are "virulence enhanced," and therefore, more clinically-relevant bacteria. With VEP, Antex will be able to identify particular genes that pathogenic bacteria express in response to the environmental conditions of the human body ("in vivo"). Microbes grown using classical laboratory methods do not behave the same as pathogenic bacteria isolated from a sick individual because they have not been exposed to important in vivo signals required for virulence production. These in vivo signals are recognized by bacteria, which respond by expressing virulence factor genes to persist and cause disease. Virulence enhanced factors include elevated levels of adhesins, invasins, enzymes and other cellular components. Some specifically up-regulated virulence factors identified in NST-grown bacteria include Type III protein translocation system substrates, flagellin expression, glycosylation of bacterial proteins, hemolysin and capsular polysaccharide production, and lipopolysaccharide structure, as well as some metabolic enzymes. Antex Biologics is a biopharmaceutical company committed to developing and marketing new products to prevent and treat infections and related diseases. In addition to its new VEP and NST platforms, Antex also applies its ART (Antigen Receptor Technology) for new product discovery. The Company has three vaccine products, discovered using these technologies, in clinical development. Also based on products produced from these technologies, the Company has strategic alliances with SmithKline Beecham, Aventis Pasteur, Pfizer and the U.S. Department of Defense. The Company's common stock is quoted on the OTC Bulletin Board under the ticker symbol ANTX. Statements contained herein that are not historical facts regarding the development of new vaccine and antibiotic products may be forward-looking statements that are subject to a variety of risks and uncertainties. There are a number of important factors that could cause actual results to differ materially from those expressed in any forward-looking statements made by the Company. Such factors are fully described in the Company's Form 10-KSB filed with the United States Securities and Exchange Commission, and include, but are not limited to: (i) the Company's ability to fund its future operations; (ii) the Company's ability to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iii) the Company's ability to obtain required governmental approvals; (iv) the Company's ability to attract and/or maintain manufacturing, sales, distribution and marketing partners; and (v) the Company's ability to develop and commercialize its products before its competitors. SOURCE Antex Biologics Inc. -0- 06/06/2000 /CONTACT: Theresa M. Stevens of Antex Biologics, 301-590-0129; or Tom Norton or Jeff McLaughlin of SPECTRUM Science Public Relations, 202-955-6222/ /Web site: antexbiologics.com